💡 Lonza will create spray-dried formulations for Iconovo’s ICOone Nasal device.
📉 This collaboration aims to reformulate treatments for obesity, eliminating the need for injections and oral medications.
🤝 Both companies prioritize patient-friendly therapies and hope for a long-term partnership.
Introduction:
The collaboration between Iconovo and Lonza marks a significant advancement in drug delivery systems, specifically focusing on the formulation development of an intranasal biologic. This partnership aims to enhance the delivery and bioavailability of therapeutics through a novel inhalation device.
- Iconovo and Lonza have initiated a collaboration to develop spray-dried formulations for an intranasally delivered biologic using Iconovo’s ICOone Nasal device.
- The project aims to reformulate an existing substance targeting obesity, representing the first step in Iconovo’s strategic initiative to replace injections with inhalation methods.
- Lonza’s expertise will focus on enhancing the bioavailability and pharmacokinetic properties of the formulations while ensuring compatibility with the ICOone Nasal device.
- The collaboration seeks to optimize key product properties such as particle size, stability, and preservation of biological activity.
- Both companies emphasize their commitment to delivering patient-friendly, non-invasive therapies that improve accessibility for those in need.
Conclusion:
This collaboration between Iconovo and Lonza represents a promising development in the field of drug delivery. By leveraging Lonza’s formulation expertise and Iconovo’s innovative inhaler technology, the partners aim to create a more efficient and patient-friendly alternative to traditional biologic delivery methods. The successful implementation of this project could have far-reaching implications, potentially transforming the management of conditions like obesity through more accessible treatment options.
